M. Hilton

发表

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

K. Hoang-Xuan, W. Mason, A. Brandes, 2014, The New England journal of medicine.

Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study).

K. McHugh, B. Geoerger, J. Merks, 2017, European journal of cancer.

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

S. Gadgeel, M. Hilton, S. Mocci, 2022, JTO clinical and research reports.

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.

W. Mason, M. Taphoorn, T. Cloughesy, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study.

A. Shaw, S. Ou, T. Mok, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.

D. Miles, D. Cameron, J. O’Shaughnessy, 2017, European journal of cancer.

Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).

W. Mason, T. Cloughesy, R. Henriksson, 2013 .

Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

K. Hoang-Xuan, W. Mason, A. Brandes, 2013 .

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.

T. Mok, E. Juhász, M. Reck, 2014, Lung cancer.

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)

T. Mok, E. Juhász, P. Delmar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

A. Shaw, S. Ou, T. Mok, 2019, Annals of Oncology.

Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.

YounJeong Choi, R. Sane, M. Hilton, 2023, Journal of biopharmaceutical statistics.

Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR.

Alexander Hillebrecht, J. Fredrickson, M. Hilton, 2023, The oncologist.

Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

W. Mason, T. Cloughesy, R. Henriksson, 2013 .

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.

A. Shaw, S. Ou, T. Mok, 2020 .

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Phase III Trial of Bevacizumab Added to Standard Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Final Progression-Free Survival and Preliminary Overall Survival Results from AVAglio (PL02.002)

W. Mason, R. Henriksson, O. Chinot, 2013 .

BERNIE: Open-label, randomized, phase II study of bevacizumab plus chemotherapy in pediatric metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).

K. McHugh, B. Geoerger, J. Merks, 2016 .